Skip to main navigation Skip to search Skip to main content

Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36

Anders Ettrup, Søren Holm, Martin Hansen, Muhammad Wasim, Martin Andreas Santini, Mikael Palner, Jacob Madsen, Claus Svarer, Jesper Langgaard Kristensen, Gitte Moos Knudsen

46 Citations (Scopus)

Abstract

[11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.
Original languageEnglish
JournalMolecular Imaging and Biology
Volume15
Issue number4
Pages (from-to)376-83
Number of pages8
ISSN1536-1632
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Dive into the research topics of 'Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36'. Together they form a unique fingerprint.

Cite this